Novartis AG Company Profile (NYSE:NVS)

About Novartis AG (NYSE:NVS)

Novartis AG logoNovartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NYSE:NVS
  • CUSIP: N/A
  • Web: www.novartis.com
Capitalization:
  • Market Cap: $203.81967 billion
  • Outstanding Shares: 2,616,845,000
Average Prices:
  • 50 Day Moving Avg: $84.30
  • 200 Day Moving Avg: $80.50
  • 52 Week Range: $66.93 - $86.90
P/E:
  • Trailing P/E Ratio: 31.46
  • Foreward P/E Ratio: 16.89
  • P/E Growth: 3.22
Sales & Book Value:
  • Annual Revenue: $49.18 billion
  • Price / Sales: 4.58
  • Book Value: $29.84 per share
  • Price / Book: 2.89
Dividend:
  • Annual Dividend: $2.30
  • Dividend Yield: 2.7%
Profitability:
  • EBIDTA: $14.46 billion
  • Net Margins: 13.52%
  • Return on Equity: 15.51%
  • Return on Assets: 8.41%
Debt:
  • Debt-to-Equity Ratio: 0.33%
  • Current Ratio: 1.01%
  • Quick Ratio: 0.75%
Misc:
  • Average Volume: 1.69 million shs.
  • Beta: 0.74
  • Short Ratio: 1.69
 

Frequently Asked Questions for Novartis AG (NYSE:NVS)

What is Novartis AG's stock symbol?

Novartis AG trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

How often does Novartis AG pay dividends? What is the dividend yield for Novartis AG?

Novartis AG announced an annual dividend on Friday, January 27th. Shareholders of record on Friday, March 3rd will be given a dividend of $2.327 per share on Friday, March 3rd. The ex-dividend date of this dividend is Wednesday, March 1st. View Novartis AG's Dividend History.

How will Novartis AG's stock buyback program work?

Novartis AG declared that its Board of Directors has initiated a stock buyback plan on Saturday, April 8th 2017, which permits the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 2.9% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's leadership believes its stock is undervalued.

How were Novartis AG's earnings last quarter?

Novartis AG (NYSE:NVS) issued its quarterly earnings results on Tuesday, July, 18th. The company reported $1.22 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.16 by $0.06. The business earned $12.24 billion during the quarter, compared to the consensus estimate of $12.20 billion. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. Novartis AG's quarterly revenue was down 1.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.23 earnings per share. View Novartis AG's Earnings History.

When will Novartis AG make its next earnings announcement?

Novartis AG is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Novartis AG.

Where is Novartis AG's stock going? Where will Novartis AG's stock price be in 2017?

15 brokerages have issued 12-month target prices for Novartis AG's shares. Their forecasts range from $74.37 to $92.00. On average, they expect Novartis AG's stock price to reach $84.44 in the next year. View Analyst Ratings for Novartis AG.

Who are some of Novartis AG's key competitors?

Who are Novartis AG's key executives?

Novartis AG's management team includes the folowing people:

  • Joseph S. Jimenez, Chief Executive Officer, Member of the Executive Committee
  • Harry Kirsch, Chief Financial Officer, Member of the Executive Committee
  • Michael Ball, Chief Executive Officer of Alcon, Member of the Executive Committee
  • James Bradner M.D., President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee
  • Richard D. Francis, Chief Executive Officer of Sandoz Division, Member of the Executive Committee
  • Paul Hudson, Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee
  • Bruno Strigini, Chief Executive Officer of Novartis Oncology, Member of the Executive Committee
  • Felix R. Ehrat Ph.D., Group General Counsel, Member of the Executive Committee
  • Steven Baert, Head of Human Resources, Member of the Executive Committee
  • Vasant Narasimhan M.D., Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee

Who owns Novartis AG stock?

Novartis AG's stock is owned by many different of institutional and retail investors. Top institutional investors include Dodge & Cox (1.92%), Franklin Resources Inc. (0.60%), Wells Fargo & Company MN (0.30%), Fisher Asset Management LLC (0.25%), The Manufacturers Life Insurance Company (0.21%) and Manning & Napier Advisors LLC (0.18%). Company insiders that own Novartis AG stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Institutional Ownership Trends for Novartis AG.

Who sold Novartis AG stock? Who is selling Novartis AG stock?

Novartis AG's stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Wells Fargo & Company MN, Renaissance Technologies LLC, Mawer Investment Management Ltd., Dodge & Cox, BB&T Securities LLC, Manning & Napier Advisors LLC and Royal Bank of Canada. View Insider Buying and Selling for Novartis AG.

Who bought Novartis AG stock? Who is buying Novartis AG stock?

Novartis AG's stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, FMR LLC, Principal Financial Group Inc., BlackRock Inc., Bain Capital Public Equity Management LLC, Fisher Asset Management LLC, Sei Investments Co. and Lord Abbett & CO. LLC. Company insiders that have bought Novartis AG stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Insider Buying and Selling for Novartis AG.

How do I buy Novartis AG stock?

Shares of Novartis AG can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novartis AG's stock price today?

One share of Novartis AG stock can currently be purchased for approximately $86.16.


MarketBeat Community Rating for Novartis AG (NYSE NVS)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  266 (Vote Outperform)
Underperform Votes:  312 (Vote Underperform)
Total Votes:  578
MarketBeat's community ratings are surveys of what our community members think about Novartis AG and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Novartis AG (NYSE:NVS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 7 Hold Ratings, 6 Buy Ratings
Consensus Rating:Hold (Score: 2.27)
Consensus Price Target: $84.44 (2.00% downside)

Analysts' Ratings History for Novartis AG (NYSE:NVS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/5/2017J P Morgan Chase & CoReiterated RatingNeutralLowView Rating Details
8/9/2017Cowen and CompanySet Price TargetHold$90.00MediumView Rating Details
7/26/2017Morgan StanleyUpgradeUnderweight -> OverweightLowView Rating Details
7/5/2017Credit Suisse GroupDowngradeNeutral -> Underperform$82.25MediumView Rating Details
6/22/2017Leerink SwannReiterated RatingMarket Perform$83.00LowView Rating Details
6/22/2017Barclays PLCUpgradeUnderweight -> Equal WeightLowView Rating Details
3/22/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutralLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageBuy -> BuyLowView Rating Details
3/7/2017Societe GeneraleUpgradeHold -> Buy$73.82 -> $74.37N/AView Rating Details
3/7/2017BNP ParibasDowngradeNeutral -> UnderperformN/AView Rating Details
1/31/2017ArgusUpgradeHold -> BuyN/AView Rating Details
1/17/2017Berenberg BankDowngradeBuy -> HoldN/AView Rating Details
1/9/2017Deutsche Bank AGReiterated RatingNeutralN/AView Rating Details
10/16/2016Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
10/10/2016Chardan CapitalLower Price TargetBuy$95.00 -> $92.00N/AView Rating Details
7/12/2016Bank of America CorporationReiterated RatingHoldN/AView Rating Details
5/24/2016Citigroup Inc.Reiterated RatingNeutralN/AView Rating Details
11/23/2015VontobelDowngradeHoldN/AView Rating Details
10/28/2015Sanford C. BernsteinLower Price TargetOutperform$102.00N/AView Rating Details
10/28/2015Main First Bank AGDowngradeUnderperformN/AView Rating Details
(Data available from 9/25/2015 forward)

Earnings

Earnings History for Novartis AG (NYSE:NVS)
Earnings by Quarter for Novartis AG (NYSE:NVS)
Earnings History by Quarter for Novartis AG (NYSE NVS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/24/2017$1.25N/AView Earnings Details
7/18/2017Q2 17$1.16$1.22$12.20 billion$12.24 billionViewN/AView Earnings Details
4/25/20173/31/2017$1.10$1.13$11.59 billion$11.54 billionViewN/AView Earnings Details
1/25/2017Q416$1.12$1.12$12.44 billion$12.32 billionViewN/AView Earnings Details
10/25/2016Q316$1.19$1.23$12.24 billion$12.13 billionViewListenView Earnings Details
7/19/2016Q216$1.18$1.23$12.33 billion$12.47 billionViewListenView Earnings Details
4/21/2016Q116$1.18$1.17$11.90 billion$11.60 billionViewListenView Earnings Details
1/27/2016Q415$1.18$1.14$12.64 billion$12.52 billionViewListenView Earnings Details
10/27/2015Q315$1.31$1.27$12.66 billion$12.30 billionViewListenView Earnings Details
7/21/2015Q215$1.20$1.27$12.45 billion$12.70 billionViewListenView Earnings Details
4/23/2015Q115$1.12$1.33$12.90 million$11.94 billionViewN/AView Earnings Details
1/27/2015Q314$1.13$1.21$14.68 billion$14.63 billionViewN/AView Earnings Details
7/17/2014Q214$1.36$1.36$14.83 billion$14.64 billionViewN/AView Earnings Details
4/24/2014Q1 2014$1.33$1.31$14.25 billion$14.02 billionViewN/AView Earnings Details
1/29/2014Q413$1.27$1.20$15.16 billion$15.08 billionViewN/AView Earnings Details
10/22/2013Q313$1.31$1.26$14.28 billion$14.34 billionViewN/AView Earnings Details
7/17/2013Q213$1.29$1.30$14.39 billion$14.50 billionViewN/AView Earnings Details
4/24/2013Q113$1.28$1.32$14.02 million$14.02 billionViewN/AView Earnings Details
1/23/2013Q412$1.19$1.27$14.42 billion$14.80 billionViewN/AView Earnings Details
10/25/2012$1.34$1.34ViewN/AView Earnings Details
7/19/2012$1.33$1.38ViewN/AView Earnings Details
4/24/2012$1.30$1.27ViewN/AView Earnings Details
1/25/2012$1.26$1.23ViewN/AView Earnings Details
10/25/2011$1.45$1.45ViewN/AView Earnings Details
7/19/2011$1.46$1.48ViewN/AView Earnings Details
4/19/2011$1.30$1.41ViewN/AView Earnings Details
1/27/2011$1.25$1.14ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Novartis AG (NYSE:NVS)
2017 EPS Consensus Estimate: $4.75
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$1.08$1.15$1.12
Q2 20172$1.15$1.22$1.19
Q3 20171$1.25$1.25$1.25
Q4 20171$1.20$1.20$1.20
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Novartis AG (NYSE:NVS)
Most Recent Dividend:3/3/2017
Annual Dividend:$2.30
Dividend Yield:2.67%
Dividend Growth:3.90% (3 Year Average)
Payout Ratio:83.94% (Trailing 12 Months of Earnings)
48.32% (Based on This Year's Estimates)
45.10% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Novartis AG (NYSE:NVS)

Dividend History by Quarter for Novartis AG (NYSE NVS)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/27/2017Annual$2.333/1/20173/3/20173/3/2017
2/1/2016Annual$2.342/24/20162/26/20162/26/2016
2/4/2014annual$2.723.48%2/27/20143/3/20143/11/2014
2/11/2013annual$2.533.71%2/26/20132/28/20134/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Novartis AG (NYSE:NVS)
Insider Ownership Percentage: 0.01%
Institutional Ownership Percentage: 10.93%
Insider Trades by Quarter for Novartis AG (NYSE:NVS)
Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)
Insider Trades by Quarter for Novartis AG (NYSE:NVS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/5/2017Bioventures Ltd NovartisMajor ShareholderBuy266,667$15.00$4,000,005.00View SEC Filing  
5/11/2016Institutes For Biomed NovartisMajor ShareholderBuy277,777$18.00$4,999,986.00View SEC Filing  
2/17/2016Bioventures Ltd NovartisMajor ShareholderBuy375,000$8.00$3,000,000.00View SEC Filing  
9/22/2014Bioventures Ltd NovartisMajor ShareholderBuy325,000$15.00$4,875,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Novartis AG (NYSE:NVS)
Latest Headlines for Novartis AG (NYSE:NVS)
Source:
DateHeadline
finanznachrichten.de logoPro-Trader Daily: Corporate News Blog - Novartis Receives EC's Approval for Rydapt; Set to Treat FLT3-Mutated Active Myeloid Leukemia
www.finanznachrichten.de - September 22 at 11:59 AM
finance.yahoo.com logoHow Did Novartis’s Established Medicines Perform in 1H17?
finance.yahoo.com - September 22 at 11:59 AM
finance.yahoo.com logoCorporate News Blog - Novartis Receives EC’s Approval for Rydapt; Set to Treat FLT3-Mutated Active Myeloid Leukemia
finance.yahoo.com - September 22 at 11:59 AM
finance.yahoo.com logo[$$] Alnylam's New Medicine To Enter Pricing Debate
finance.yahoo.com - September 22 at 11:59 AM
finance.yahoo.com logoGilenya and Entresto Could Keep Boosting Novartis’s Revenue Growth
finance.yahoo.com - September 22 at 11:59 AM
americanbankingnews.com logoNovartis AG (NVS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - September 21 at 12:00 PM
finance.yahoo.com logoAn Update on Novartis’s Sandostatin, Afinitor, and Exjade
finance.yahoo.com - September 20 at 7:06 AM
americanbankingnews.com logoNovartis AG (NVS) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - September 19 at 10:12 AM
finanznachrichten.de logoNovartis: Xolair Confirms Re-treatment Efficacy In CSU Patients
www.finanznachrichten.de - September 19 at 5:54 AM
seekingalpha.com logoNovartis: The Value Creator
seekingalpha.com - September 19 at 5:54 AM
finance.yahoo.com logoHow Is Novartis’s Lucentis Positioned after 1H17?
finance.yahoo.com - September 19 at 5:54 AM
finance.yahoo.com logoHow Did Novartis Perform in 1H17?
finance.yahoo.com - September 19 at 5:54 AM
finance.yahoo.com logoKisqali Could Significantly Boost Novartis’s Revenue Growth
finance.yahoo.com - September 19 at 5:54 AM
finance.yahoo.com logoNovartis Announces Positive Data on Urticaria Drug Xolair
finance.yahoo.com - September 19 at 5:54 AM
americanbankingnews.com logoNovartis AG (NVS) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 17 at 5:08 PM
finance.yahoo.com logoNovartis Sees IBD RS Rating Rise To 72
finance.yahoo.com - September 17 at 6:18 AM
finance.yahoo.com logoNovartis Sees IBD RS Rating Rise To 72
finance.yahoo.com - September 17 at 6:18 AM
finanznachrichten.de logoTransCelerate BioPharma Adds Novartis; Elects Amgen's Elliott Levy As Chair
www.finanznachrichten.de - September 14 at 8:30 AM
finance.yahoo.com logoNovartis' BLA for Biosimilar of Rituxan Accepted by the FDA
finance.yahoo.com - September 13 at 7:19 AM
finance.yahoo.com logoNovartis' BLA for Biosimilar of Rituxan Accepted by the FDA
finance.yahoo.com - September 13 at 7:19 AM
finance.yahoo.com logoRoche's Ophthalmology Drug Fails to Meet Primary Endpoint
finance.yahoo.com - September 12 at 7:18 AM
finance.yahoo.com logoNovartis posts a win, Roche a flop in skin cancer trials
finance.yahoo.com - September 11 at 1:17 AM
finanznachrichten.de logoNovartis: New Data Confirm Lucentis Efficacy And Durability Vs Aflibercept
www.finanznachrichten.de - September 10 at 5:08 AM
finance.yahoo.com logoLilly takes on Pfizer, Novartis with new breast cancer drug data
finance.yahoo.com - September 10 at 5:08 AM
finance.yahoo.com logoNovartis Sees Relative Strength Rating Improve To 75
finance.yahoo.com - September 9 at 6:49 AM
finance.yahoo.com logo[$$] Investors Chronicle: Redrow, Oxford BioMedica, Halfords
finance.yahoo.com - September 9 at 6:49 AM
americanbankingnews.com logoFinancial Contrast: Aralez Pharmaceuticals (ARLZ) vs. Novartis AG (NVS)
www.americanbankingnews.com - September 8 at 10:28 PM
finance.yahoo.com logoDeparting Novartis CEO Sets His Eyes On Silicon Valley
finance.yahoo.com - September 8 at 6:34 AM
finance.yahoo.com logo[$$] Novartis Deal Could Send Xoma Stock to $19
finance.yahoo.com - September 7 at 7:04 AM
finance.yahoo.com logoNovartis' (NVS) MS Drug Gilenya Positive in Long-Term Study
finance.yahoo.com - September 7 at 7:04 AM
finance.yahoo.com logo5 Things Gilead Sciences' Management Just Said That You'll Want to Know
finance.yahoo.com - September 7 at 7:04 AM
finanznachrichten.de logoNovartis Announces Positive Results From Phase III PARADIGMS Study
www.finanznachrichten.de - September 6 at 7:05 AM
finance.yahoo.com logoNovartis Calls the Doctor to Push Breakthrough Drugs Forward
finance.yahoo.com - September 6 at 7:05 AM
finance.yahoo.com logo[$$] Novartis CEO to Step Down in January
finance.yahoo.com - September 6 at 7:05 AM
finance.yahoo.com logoNovartis CEO to step down next year
finance.yahoo.com - September 6 at 7:05 AM
finance.yahoo.com logo3 Stocks to Watch on Tuesday: Boeing Co (BA), McDonald’s Corporation (MCD) and Novartis AG (ADR) (NVS)
finance.yahoo.com - September 6 at 7:05 AM
americanbankingnews.com logoNovartis AG (NVS) vs. Collegium Pharmaceutical (COLL) Financial Comparison
www.americanbankingnews.com - September 5 at 8:46 PM
bloomberg.com logoNovartis Calls the Doctor to Push Breakthrough Drugs Forward - Bloomberg
www.bloomberg.com - September 5 at 9:07 AM
investorplace.com logo3 Stocks to Watch on Tuesday: Boeing Co (BA), McDonald’s Corporation (MCD) and Novartis AG (ADR) (NVS)
investorplace.com - September 5 at 8:48 AM
americanbankingnews.com logoNovartis AG (NVS) Stock Rating Reaffirmed by J P Morgan Chase & Co
www.americanbankingnews.com - September 5 at 8:26 AM
marketwatch.com logoWeekend roundup: Campbell in the soup | New cancer gene therapy | Exposing bad investment advice
www.marketwatch.com - September 4 at 8:02 PM
finance.yahoo.com logoNovartis CEO Joseph Jimenez Is Stepping Down
finance.yahoo.com - September 4 at 8:02 PM
finance.yahoo.com logoNovartis Names Narasimhan CEO as Jimenez Retires
finance.yahoo.com - September 4 at 8:02 PM
finance.yahoo.com logoNovartis names drugs chief as CEO to deliver return to growth
finance.yahoo.com - September 4 at 8:02 PM
finance.yahoo.com logo[$$] Novartis: doctor in the house
finance.yahoo.com - September 4 at 8:02 PM
finance.yahoo.com logo[$$] Novartis names chief to replace Jimenez who is to step down
finance.yahoo.com - September 4 at 8:02 PM
bloomberg.com logoNovartis CEO Jimenez to Depart, Handing Reins to Harvard Doctor - Bloomberg
www.bloomberg.com - September 4 at 6:31 AM
finance.yahoo.com logoNovartis CEO: Here's How We Handled A Milestone In Pediatric Cancer
finance.yahoo.com - September 2 at 6:56 AM
finance.yahoo.com logoCancer Breakthroughs Can Quickly Become Tomorrow's Also-Ran
finance.yahoo.com - September 2 at 6:56 AM
finance.yahoo.com logo[$$] Week in Review, September 2
finance.yahoo.com - September 2 at 6:56 AM

Social

Chart

Novartis AG (NVS) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by MarketBeat.com Staff